Walleye Capital
LABP

Walleye Capital’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Walleye Capital’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-9,353
Closed -$138K – 2816
2022
Q1 		$138K Sell
9,353
-1,168
-11% -$29.7K ﹤0.01% 1658
2021
Q4 		$505K Buy
+10,521
New +$1.11M 0.02% 980

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $420M AUM 42.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's LABP Position: Q2 2022 in Review

Walleye Capital sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2022, closing a stake of 9,353 shares — an estimated $138K sold.

Walleye Capital first reported a position in LABP in Q4 2021 and held it in 2 quarters. The position peaked at $505K in Q4 2021. 34 funds tracked by Wall St. Rank hold LABP as of Q2 2022.

  • Walleye Capital reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Walleye Capital sold 9,353 Landos Biopharma, Inc. Common Stock shares in Q2 2022, an estimated $138K.
  • Walleye Capital first reported a position in Landos Biopharma, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Walleye Capital's Landos Biopharma, Inc. Common Stock position peaked at $505K in Q4 2021.
  • 34 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2022.

Based on Walleye Capital's 13F filing for Q2 2022, filed 8 Aug 2022.